Eli Lilly's stock is up 2.1% today at $34,600 following the launch of its Medicare GLP-1 Bridge program. - The program, effective July 1, 2026, significantly expands access for eligible Medicare Part D beneficiaries to key weight-loss drugs, including Zepbound (tirzepatide) and Foundayo. - This landmark initiative marks the first broad Medicare Part D coverage pathway for GLP-1 obesity medicines, reinforcing investor optimism for Eli Lilly's metabolic franchise.